Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination

**Abstract**

Purpose: Hepatitis B virus (HBV) vaccination is recommended for all human immunodeficiency virus (HIV)-infected patients without HBV immunity. However, serological response to standard HBV vaccination is frequently suboptimal in this population and the appropriate strategy for revaccination of HIV-infected nonresponders remained controversial. We aimed to determine the serological response to one booster dose of HBV vaccine given by intradermal (ID) or intramuscular (IM) route in HIV-positive nonresponders to standard HBV vaccination.

Materials and Methods: In this study, 42 HIV-infected nonresponders were enrolled. We randomized them to receive either 10 μg (0.5 mL) for ID (20 cases) or 20 μg (1 mL) for IM (22 cases) administration of HBV vaccine as a one booster dose. After 1 month, anti-HBs titer was checked in all cases. A protective antibody response (seroconversion) defined as an anti-HBs titer ≥10 IU/L. Results: Seroconversion was observed in 47.6% of subjects after 1 ID dose. A total of 30% showed antibody titers above 100 IU/L. Except one case, all responders had CD4+ >200 cells/mm³. Mean anti-HBs titer was 146.5 ± 246 IU/L. After the one IM booster dose, seroconversion was observed in 50% of cases. A total of 36.3% of subjects had anti-HBs ≥100 IU/L. All responders had CD4+ >200 cells/mm³, except one case. Mean anti-HBs titer was 416.4 ± 765.6 IU/L. Responders showed significantly higher CD4+ cell counts, in
INTRODUCTION

Because Human Immunodeficiency Virus (HIV) and hepatitis B virus (HBV) share similar routes of transmission, HIV/HBV coinfection rate is considerable (6.3-9.7%).[1-3] This coinfection is associated with higher HBV viremia, HBV reactivation, chronic HBV infection, cirrhosis and eight fold increase in liver-related mortality.[3,4] In addition, HBV also can affect HIV treatment as a result of hepatotoxicity of antiretroviral medicine.[5] Therefore, HBV vaccine is highly recommended to all asymptomatic HIV-infected patients without immunity to HBV according to current guideline.[6-8]

HIV-infected individuals have suboptimal response to HBV vaccine with immunogenicity rates varying from 17.5% to 72%.[9-11] High CD4+ cell counts and low HIV viremia are important factors associated with proper hepatitis B vaccine response.[12]

It is not clear how nonresponders to HBV vaccine should be managed. Common practice is to administer a second course of three doses of intramuscular vaccine, but this approach has variable success.[13] Previous studies suggested that modification of the standard HBV vaccination schedule such as administering additional doses or doubling the standard antigen dose, or both, may be effective in increasing vaccine response.[11,14] An alternate approach is intradermal administration (ID) of HBV vaccine which facilitates the exposure of antigen to antigen-presenting cells, dendritic cells, and macrophages.[15-18]

However, few studies are performed in the setting of HBV revaccination schedules in HIV-infected nonresponders and the appropriate strategy in this population remains controversial.[11,17,19] Therefore, we aimed to determine the serological response to one booster dose of HBV vaccine given randomly by ID or intramuscular (IM) in two groups of HIV-infected patients who failed to respond to standard HBV vaccination.

MATERIALS AND METHODS

In this study, 42 HIV-infected patient who attend to triangular clinics (sexually transmitted infections, HIV/AIDS, drug abuse) and failed to respond to standard three doses of IM HBV vaccination [anti-HBs titers <10 IU/L by enzyme-linked immunosorbent assay (ELISA) assay] were enrolled from January to September 2012. Duration between the standard HBV vaccination and booster dose was between 1 to 2 years. This project was approved by Arak University of Medical Sciences Ethical Committee and informed consent was obtained from patients prior to their enrollment. A questionnaire that gathered characteristic and laboratory data was completed by clinicians.

Patients were randomized into two groups. A total of 22 cases received one intramuscular injections of the standard dose 20 μg (1 mL), and 20 individuals received one intradermal injection of 10 μg (0.5 mL) recombinant HBV vaccine (Pasteur Institute of Iran, Tehran, Iran). One month later, a blood sample was taken for measuring hepatitis B surface antibody (anti-HBs) titer (Enzygnost, Dade Behring Marburg GmbH, Germany) by ELISA. Hepatitis C antibody (anti-HCV) was also checked by ELISA in all samples. The used kit was Biorad, Segrate, Italy. Recombinant immunoblot assay (RIBA Innogenetics, Ghent, Belgium) was employed to confirm anti-HCV reactivity. CD4+ cell counts was determined by flowcytometry and defined as cells/mm3.

Definitions

Standard HBV vaccination includes administration of three intramuscular injections of the standard dose (20 μg or 1 mL) of recombinant HBV vaccine at months 0, 1, and 6.

Nonresponders, defined as cases with anti-HBs titer <10 IU/L, were offered for revaccination.

Anti-HBs ≥10 IU/L was considered protective and anti-HBs ≥100 IU/L was considered fully protective.

Statistical analysis

The Chi-square test was used with the SPSS 16 Package program for statistical analysis (Chicago, IL, USA). Data are presented as mean ± standard deviation or, when indicated, as an absolute number and percentage.

Comparison to nonresponders (P < 0.001).

Conclusions: One booster dose administered IM or ID to HIV-infected nonresponders resulted in similar rates of seroconversion, overall response rate 50%. However, higher anti-HBs titers observed more frequently in IM group.

Key words: Booster dose, hepatitis B virus vaccination, human immunodeficiency virus, intradermal, intramuscular, nonresponder
In each group (IM, ID), individuals with adequate serological response compared with nonresponders respect to age, sex, CD4+ cell counts, HCV infection, and use of antiretroviral therapy (ART).

RESULTS

In this study 42 HIV-infected nonresponders were enrolled. The mean age of patients was 33.3 ± 1.08 years. 57.1% of patients were males and 42.9% were females. The mean and median CD4+ cell counts were 454.5476 ± 551.8 and 267.5 cells/mm³ respectively, and 31% of HIV cases had CD4+ ≤ 200 cells/mm³. A total of 78.6% of patients received ART. Anti-HCV was positive in 38% of cases. One IM or ID booster dose was administered to 22 and 20 HIV-infected nonresponders, respectively.

In ID group, mean CD4+ cell counts of patients was 693.9 ± 723.6 cells/mm³. Seroconversion was observed in 47.6% subjects after one ID dose. A total of 30% showed antibody titers above 100 IU/L, which was considered to be fully protective. Only one subject (5%) showed anti-HBs ≥ 1000 IU/L. From five cases with CD4+ ≤ 200 cells/mm³, only one case responded to ID booster dose with anti-HBs titer of 35.8 IU/L. Anti-HCV was positive in 45% of ID group. Except one case, all responders had CD4+ > 200 cells/mm³. Mean anti-HBs titer was 146.5 ± 246 IU/L.

In IM group, mean CD4+ cell counts of patients was 237 ± 128.8 cells/mm³. After the one IM booster dose, a protective antibody response was observed in 50% of cases. Fully protective antibody was detected in 36.3% of subjects. A total of three subjects (13.6%) showed anti-HBs ≥ 1000 IU/L. HCV infection was seen in 31.8% of IM group. From eight cases with CD4+ ≤ 200 cells/mm³, only one case responded to ID booster dose (anti-HBs ≥ 1000 IU/L). All responders had CD4+ > 200 cells/mm³, except one case. Mean titer of anti-HBs was 416.4 ± 765.6 IU/L.

There was not any significant difference between responders and nonresponders except for CD4+ cell counts. Responders showed significantly higher CD4+ cell counts, in comparison to nonresponders (P < 0.001).

Both intramuscular and intradermal booster dose improved serological response in HIV-infected patients who failed to response to standard HBV vaccination. But there was not any significant difference in respect to anti-HBs response rate and titer between IM and ID groups. Although, IM group with lower CD4+ cell counts, showed higher anti-HBs titer.

The vaccine was well-tolerated in all patients with no side effects.

DISCUSSION

The present study investigated the results of two routes of booster dose rechallenge in HIV-infected patients not responding to their initial vaccination. This survey showed improves in the response rate (overall 50%) after both intramuscular and intradermal booster dose of HBV vaccine. IM group with lower CD4+ cell counts showed higher anti-HBs titer and a little more seroconversion rate than ID group. Overall responders showed significantly higher CD4+ cell counts, in comparison to nonresponders.

There are several clinical trials regarding HBV vaccination by ID route in health care workers, hemodialysis patients, and kidney transplant recipients with suboptimal response to vaccine.[13,16,20] But few data exist regarding HBV vaccination by ID route in HIV-infected individuals. Shafran et al.,[17] administered 0.25 mL HBV vaccine ID every 2 weeks in four doses in HIV-infected nonresponders with history of failure to prior HBV vaccination and found 50% antibody response. In a study by Ristola et al.,[21] ID route induced protective immunity in 50% of six HIV-infected subjects not responding to standard IM schedule. Launay et al.,[18] data showed that primary HBV vaccination with 4 μg ID for four times is significantly more efficient than the standard HBV vaccination (77% versus 65% respectively). Therefore, taken together it seems that ID route can improve seroconversion rate in HIV-infected subjects who failed to respond to primary vaccination.

Revaccination with intramuscular booster dose in HIV-infected nonresponders was investigated in some studies. Rey et al.,[11] data indicated that rechallenging of HIV-infected nonresponders (to initial HBV vaccination) with three additional monthly injections could be effective (77.7%). In a study conducted by Bunupuradah et al.,[18] on HIV-infected children which 64% of them had received HBV vaccine during infancy, only 56.1% of the ID arm had good response to vaccine compared to 82.1% in the IM arm. Besides, a study in the Netherlands showed HBV revaccination with double dose of vaccine intramuscularly at 0, 1, and 2 months was effective (77.7%). In a study conducted by Bunupuradah et al.,[18] on HIV-infected children which 64% of them had received HBV vaccine during infancy, only 56.1% of the ID arm had good response to vaccine compared to 82.1% in the IM arm. Besides, a study in the Netherlands showed HBV revaccination with double dose of vaccine intramuscularly at 0, 1, and 2 months was effective (77.7%). In a study conducted by Bunupuradah et al.,[18] on HIV-infected children which 64% of them had received HBV vaccine during infancy, only 56.1% of the ID arm had good response to vaccine compared to 82.1% in the IM arm. Besides, a study in the Netherlands showed HBV revaccination with double dose of vaccine intramuscularly at 0, 1, and 2 months was effective (77.7%).
vaccination showed high seroconversion rate 82% versus standard schedule 65%. Studies comparing response rates of two routes of HBV vaccine booster regimen in HIV positive nonresponders to standard HBV vaccination was shown in Table 1.

However, the optimal HBV revaccination schedule in HIV-infected nonresponders is still a subject of controversy. Our study is the first randomized trial which evaluate one dose of ID (0.5 mL) and IM (1 mL) as a booster dose vaccination in HIV-infected patients who failed to respond to initial HBV vaccination. However, our study has some limitations. First, the number of subjects was small. Second, we did not consider the effect of HIV viral load in this study. Third, despite to randomly HBV booster vaccination, patients with lower CD4 count were placed in IM group, so we could not compare two groups and draw a definite conclusion in respect to seroconversion rate and the best approach of revaccination.

**CONCLUSION**

Our study revealed that one booster dose administered IM or ID to HIV-infected nonresponders was effective and resulted in similar rates of seroconversion, overall response rate 50%. The only significant finding associated with higher response rate was CD4+ ≥200 cell/mm³. Despite to limitation of our study, higher antibody titers to HBV vaccine observed more frequently in IM group. However, further studies are needed to define the best approach to increase protective antibody responses to HBV immunization in the HIV setting.

**ACKNOWLEDGMENT**

The authors are grateful to Arak University of Medical Sciences for financial support of this study. This study belongs to Maryam Gol-Mohammadi, MD thesis.

### REFERENCES

1. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. EuroSIDA Group. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601.
2. Kellerman SE, Hanson DO, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and the incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:571-7.
3. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, et al. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
4. Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002;4:27-35.
5. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injection drug use and HIV among people who inject drugs: A systematic review. Lancet 2008;372:1733-45.
6. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palgi G, et al. ECC Jury. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-24.
7. Masur H, Kaplan JE, Holmes KK. U.S. Public Health Service, Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons 2002: Recommendations of the US Public Health Service and the Infectious Diseases Society of America. US Public Health Service, Infectious Diseases Society of America. Ann Intern Med 2002;137:433-75.
8. Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005;118 Suppl 1A:75-83S.
9. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23:2902-8.
10. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008;19:600-4.
11. Rey D, Kranz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients: Effects on HIV-1 viral load. Vaccine 2000;18:1161-5.
12. Bongiovanni M, Casana M. Hepatitis B vaccination in HIV-infected subjects. Curr Mol Pharmacol 2008;1:191-4.
13. Sjogren MH. Prevention of hepatitis B in nonresponders to initial hepatitis B vaccination. Am J Med 2005;118:34-95.
14. Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, et al. ANRS HB03 VIHVAC-B Trial. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B Vaccine regimen in adults with HIV-1: A randomized controlled trial. JAMA 2011;305:1432-40.
15. Choy BY, Peris JS, Chan TM, Lo SK, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am J Transplant 2002;2:965-9.
16. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002;23:87-90.
17. Shafran SD, Mashinter LD, Lindemulder A, Taylor GD, Chiu I. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine. HIV Med 2007;8:295-9.
18. Brunupradah T, Anamvoranich J, Pancharoen C, Petoumenos K, Gol-Mohammadi, MD thesis.
Prasitsuebsai W, Wongngam W, et al. Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine 2011;29:2962-7.

19. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM, Mudrikova T, et al. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis 2011;203:984-91.

20. Waite NM, Thomason LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously non-responsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995;5:1930-4.

21. Ristola MA, Vuola JM, Valle M, von Reyn CF. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine 2004;23:205-9.

22. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27:17-22.

23. Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X, et al. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Hum Vaccin Immunother 2012;8:1845-9.

How to cite this article: Ramezani A, Janbakhsh A, Gol-Mohammadi M, Banifazl M, Aghakhani A, Eslamifar A, et al. Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination. Perspect Clin Res 2014;5:134-8.

Source of Support: Arak University of Medical Sciences.

Conflict of Interest: None declared.